Subscribe
Logo small
Search

AOTMiT: Transparency Council on Parkinson's disease, epilepsy and primary hypercholesterolemia, among others

MedExpress Team

medexpress.pl

Published March 4, 2024 08:50

Today (March 4) another meeting of the Transparency Council.
AOTMiT: Transparency Council on Parkinson's disease, epilepsy and primary hypercholesterolemia, among others - Header image
Źródło: AOTMiT

The agenda includes:

  1. Preparation of a position paper on the evaluation of the drug Ngenla (somatrogonum) within the framework of the drug program B.19. "Treatment of low-grade children with somatotropin hypopituitarism (ICD-10: E23)".
  2. Preparation of a position paper on the evaluation of the drug Produodopa (foslevodopum + foscarbidopum) under the drug program B.90. "Treatment of motor disorders in the course of advanced parkinson's disease (ICD-10: G.20)".
  3. Preparation of a position paper on the evaluation of the drug Vyndaqel (tafamidisum) under the drug program "Treatment of patients with cardiomyopathy in the course of transthyretin amyloidosis (ICD 10 E85)".
  4. Preparation of a position paper on the issuance of approvals for reimbursement of the foodstuff for special nutritional use Kindergen for the indication: chronic renal failure in pediatric patients.
  5. Preparation of a position paper on examining the appropriateness of issuing reimbursement approvals for the medicinal product Nilemdo (bempedic acid) for the indication: primary hypercholesterolemia (heterozygous familial and non-familial) in adults with statin intolerance.
  6. Preparation of a position on the legitimacy of issuing approvals for reimbursement of medicinal products:
  • Synacthen,
  • Synacthen Depot (tetracosactide)

For indications: drug-resistant epilepsy, drug-resistant epilepsy under West syndrome, drug-resistant epilepsy under Lennox-Gastaut syndrome, Kinsbourne syndrome, Landau Kleffner syndrome in pediatric and adult patients.

  1. Preparation of an opinion on the continuation of reimbursement coverage of drugs containing the active substance bevacizumab in the indication: treatment of diabetic macular edema (DME) (ICD-10: H36.0).
  2. Preparation of an opinion on the draft health policy program of the local government unit "Prevention of cancer of the lower digestive tract for people aged 50-74 years implemented in the Wielkopolska province".

Source: AOTMiT

Szukaj nowych pracowników

Dodaj ogłoszenie o pracę za darmo

Lub znajdź wyjątkowe miejsce pracy!